WO2014153117A3 - Anticorps dirigés contre hgf et compositions les contenant - Google Patents
Anticorps dirigés contre hgf et compositions les contenant Download PDFInfo
- Publication number
- WO2014153117A3 WO2014153117A3 PCT/US2014/029163 US2014029163W WO2014153117A3 WO 2014153117 A3 WO2014153117 A3 WO 2014153117A3 US 2014029163 W US2014029163 W US 2014029163W WO 2014153117 A3 WO2014153117 A3 WO 2014153117A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hgf
- antibodies
- binding fragments
- compositions containing
- fragments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14767985.6A EP2964673A4 (fr) | 2013-03-14 | 2014-03-14 | Anticorps dirigés contre hgf et compositions les contenant |
CA2904743A CA2904743A1 (fr) | 2013-03-14 | 2014-03-14 | Anticorps diriges contre hgf et compositions les contenant |
JP2016503002A JP2016516052A (ja) | 2013-03-14 | 2014-03-14 | Hgfに対する抗体及びそれらを含む組成物 |
KR1020157029279A KR20150140685A (ko) | 2013-03-14 | 2014-03-14 | Hgf에 대한 항체 및 이를 포함하는 조성물 |
CN201480026978.3A CN105246915A (zh) | 2013-03-14 | 2014-03-14 | Hgf抗体及含有其的组合物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361782868P | 2013-03-14 | 2013-03-14 | |
US201361781643P | 2013-03-14 | 2013-03-14 | |
US61/782,868 | 2013-03-14 | ||
US61/781,643 | 2013-03-14 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2014153117A2 WO2014153117A2 (fr) | 2014-09-25 |
WO2014153117A9 WO2014153117A9 (fr) | 2014-11-27 |
WO2014153117A3 true WO2014153117A3 (fr) | 2015-01-08 |
Family
ID=51581767
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/029163 WO2014153117A2 (fr) | 2013-03-14 | 2014-03-14 | Anticorps dirigés contre hgf et compositions les contenant |
PCT/US2014/029383 WO2014153166A2 (fr) | 2013-03-14 | 2014-03-14 | Utilisation thérapeutique d'anticorps contre hgf |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/029383 WO2014153166A2 (fr) | 2013-03-14 | 2014-03-14 | Utilisation thérapeutique d'anticorps contre hgf |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2964673A4 (fr) |
JP (1) | JP2016516052A (fr) |
KR (1) | KR20150140685A (fr) |
CN (1) | CN105246915A (fr) |
CA (1) | CA2904743A1 (fr) |
TW (2) | TW201444868A (fr) |
WO (2) | WO2014153117A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106699868B (zh) * | 2017-03-01 | 2019-11-15 | 牡丹江医学院 | 一种蛋白质及编码其的核苷酸序列 |
CN109771642B (zh) | 2017-11-13 | 2022-09-20 | 同济大学苏州研究院 | c-MET激动型抗体及其用途 |
US11065265B2 (en) | 2018-05-18 | 2021-07-20 | Spes Pharmaceuticals Inc. | Compositions of fosaprepitant and methods of preparation |
CN112569359A (zh) * | 2019-09-30 | 2021-03-30 | 上海生物制品研究所有限责任公司 | 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用 |
JP2022553820A (ja) | 2019-11-05 | 2022-12-26 | アッヴィ・インコーポレイテッド | 骨髄線維症及びmpn関連障害をナビトクラクスで処置する際に使用するための投与レジメン |
WO2022228514A1 (fr) * | 2021-04-29 | 2022-11-03 | 北京浩古元方生物医药科技有限公司 | Anticorps anti-facteur inhibiteur de la leucémie humaine et son utilisation |
WO2024129564A1 (fr) * | 2022-12-13 | 2024-06-20 | The Children's Medical Center Corporation | Méthodes et compositions pour le traitement d'anomalies vasculaires |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7718174B2 (en) * | 2006-07-14 | 2010-05-18 | Abxign, Inc. | Anti-HGF/SF humanized antibody |
US20100129357A1 (en) * | 2008-11-25 | 2010-05-27 | Leon Garcia-Martinez | Antibodies to il-6 and use thereof |
US20130344068A1 (en) * | 2010-12-01 | 2013-12-26 | Leon F. Garcia-Martinez | Methods of preventing inflammation and treating pain using anti-ngf compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6214344B1 (en) * | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
RS53476B (en) * | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Hepatocyte Growth Factor Binders |
AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
NZ572807A (en) * | 2006-05-19 | 2011-10-28 | Alder Biopharmaceuticals Inc | Culture method for obtaining a clonal population of antigen-specific b cells |
CN101460520B (zh) * | 2006-06-02 | 2012-12-26 | Aveo制药公司 | 肝细胞生长因子(hgf)的结合蛋白质 |
EP2361934A3 (fr) * | 2006-06-02 | 2011-11-02 | Aveo Pharmaceuticals, Inc. | Protéines de liaison de facteur de croissance d'hépatocyte |
BRPI0712223A2 (pt) * | 2006-06-02 | 2012-07-10 | Aveo Pharmaceuticals Inc | proteìnas de ligação ao fator de crescimento de hepatócito (hgf) |
-
2014
- 2014-03-14 WO PCT/US2014/029163 patent/WO2014153117A2/fr active Application Filing
- 2014-03-14 JP JP2016503002A patent/JP2016516052A/ja active Pending
- 2014-03-14 CN CN201480026978.3A patent/CN105246915A/zh active Pending
- 2014-03-14 WO PCT/US2014/029383 patent/WO2014153166A2/fr active Application Filing
- 2014-03-14 EP EP14767985.6A patent/EP2964673A4/fr not_active Withdrawn
- 2014-03-14 TW TW103109575A patent/TW201444868A/zh unknown
- 2014-03-14 CA CA2904743A patent/CA2904743A1/fr not_active Abandoned
- 2014-03-14 TW TW103109578A patent/TW201438737A/zh unknown
- 2014-03-14 KR KR1020157029279A patent/KR20150140685A/ko not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7718174B2 (en) * | 2006-07-14 | 2010-05-18 | Abxign, Inc. | Anti-HGF/SF humanized antibody |
US20100129357A1 (en) * | 2008-11-25 | 2010-05-27 | Leon Garcia-Martinez | Antibodies to il-6 and use thereof |
US20130344068A1 (en) * | 2010-12-01 | 2013-12-26 | Leon F. Garcia-Martinez | Methods of preventing inflammation and treating pain using anti-ngf compositions |
Non-Patent Citations (2)
Title |
---|
BURGESS ET AL.: "Fully Human Monoclonal Antibodies to Hepatocyte Growth Factor with Therapeutic Potential against Hepatocyte Growth Factor/c-Met-Dependent Human Tumors'.", CANCER RESEARCH, vol. 66, 1 February 2006 (2006-02-01), pages 1721 - 1729, XP008075112 * |
See also references of EP2964673A4 * |
Also Published As
Publication number | Publication date |
---|---|
KR20150140685A (ko) | 2015-12-16 |
TW201444868A (zh) | 2014-12-01 |
CA2904743A1 (fr) | 2014-09-25 |
EP2964673A2 (fr) | 2016-01-13 |
TW201438737A (zh) | 2014-10-16 |
JP2016516052A (ja) | 2016-06-02 |
EP2964673A4 (fr) | 2017-02-22 |
WO2014153117A9 (fr) | 2014-11-27 |
WO2014153166A3 (fr) | 2014-12-04 |
WO2014153166A2 (fr) | 2014-09-25 |
WO2014153117A2 (fr) | 2014-09-25 |
CN105246915A (zh) | 2016-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500521A1 (en) | Anti-cgrp compositions and use thereof | |
NZ732652A (en) | Anti-pcsk9 antibodies and use thereof | |
WO2012075340A3 (fr) | Compositions anti-ngf et leur utilisation | |
WO2014153117A3 (fr) | Anticorps dirigés contre hgf et compositions les contenant | |
MX2018012470A (es) | Anticuerpos anti pacap humanizados y usos de ellos. | |
WO2008144753A3 (fr) | Anticorps anti-tnf alpha et leur utilisation | |
TR201905366T4 (tr) | IL-6 antikorları ve bunların kullanımı. | |
AR095556A1 (es) | Anticuerpos contra hgf y composiciones que contienen a los mismos | |
WO2015053871A3 (fr) | Acides nucléiques codant des anticorps humains contre sialyl-lewisa | |
BR112015009961A2 (pt) | imunoglobinas anti-vegf/dll4 com duplo domínio variável e uso destas | |
WO2015073580A8 (fr) | Anticorps spécifiques du ligand 1a de type facteur de nécrose tumorale et compositions ainsi qu'utilisations associées | |
WO2014089335A3 (fr) | Protéines de liaison à l'antigène bcma | |
WO2011025964A3 (fr) | Protéines thérapeutiques se liant à dll4 | |
MX2012005037A (es) | Inmunoglobulinas de dominio variable doble y usos de las mismas. | |
MX2012004415A (es) | Inmunoglobulinas de dominio variable doble y usos de las mismas. | |
SG178602A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
MX2012001262A (es) | Inmunoglobulinas de dominio variable doble y usos de las misma. | |
MX2011011669A (es) | Inmunoglobulinas de dominio variable dual y usos de las misma. | |
BR112012032778A2 (pt) | "proteínas multiespecíficas e multivalentes" | |
WO2013101972A3 (fr) | Immunoglobulines à domaine variable double et applications associées | |
WO2014144280A8 (fr) | Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1β et/ou il -17 | |
WO2016100838A3 (fr) | Anticorps anti-acth humanisés et leur utilisation | |
WO2012080926A3 (fr) | Anticorps anti-notch1 | |
WO2009105585A3 (fr) | Agents de chimiodénervation ciblés de manière postsynaptique et leurs procédés d’utilisation | |
WO2015187811A3 (fr) | Anticorps monoclonal humain contre le ganglioside gd2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14767985 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2904743 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016503002 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014767985 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20157029279 Country of ref document: KR Kind code of ref document: A |